Table 2 A subset of publications with high attention scores
From: regCOVID: Tracking publications of registered COVID-19 studies
PMID | Article title | Publication date | NCT ID | Interventiona | Attention score |
|---|---|---|---|---|---|
32,706,859 | Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care | 12/13/2021 | NCT04292899 | Remdesivir|Standard of Care | 5.116827 |
34,863,332 | Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial | 12/11/2021 | NCT04351152 | Lenzilumab|Standard of Care | 5.116714 |
33,972,949 | LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL | 5/15/2021 | NCT04351152 | Lenzilumab|Standard of Care | 5.104832 |
34,672,949 | Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial | 1/13/2022 | NCT04492475 | Interferon beta-1a|Placebo|Remdesivir | 5.103581 |
34,407,339 | Early Convalescent Plasma for High-Risk Outpatients with Covid-19 | 11/30/2021 | NCT04355767 | Convalescent Plasma|Saline | 5.101792 |
33,204,764 | Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19 | 6/22/2021 | NCT04328467 | Hydroxychloroquine|Placebo | 5.099582 |
31,282,542 | A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation | 2/5/2021 | NCT04410328 | Dipyridamole ER 200 mg/ Aspirin 25 mg orally/enterally AND Standard of care|Standard of care | 5.09923 |